September 15, 2025 a 07:43 am
BMY: Fundamental Ratio Analysis - Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, a leader in the biopharmaceutical industry, presents diverse opportunities with its broad product portfolio targeting critical health areas including cancer and cardiovascular diseases. Leveraging cutting-edge therapies, the company continues to show strong potential in a rapidly evolving market. However, investors should consider its high debt-to-equity ratio when making investment decisions.
Fundamental Rating
The current fundamental rating indicates a strong position in discounted cash flow and return on equity, but weakness is observed in debt management.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Historical Rating
Historical data shows consistent performance in key areas, reflecting stability and potential for growth.
| Date | Overall Score | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-09-12 | 3 | 5 | 5 | 4 | 1 | 2 | 1 |
| n.a. | 0 | 5 | 5 | 4 | 1 | 2 | 1 |
Analyst Price Targets
Analysts provide a mixed outlook, with a median target suggesting moderate growth potential. Predictions range notably from $42 to $84.
| High | Low | Median | Consensus |
|---|---|---|---|
| $84 | $42 | $66.5 | $64.75 |
Analyst Sentiment
The overall sentiment remains cautious with a tendency towards holding the stock, reflecting market volatility and sector-specific dynamics.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 15 | |
| Hold | 23 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Bristol-Myers Squibb Company stands as a significant player in the healthcare sector with a solid product lineup. The stock's fundamental ratings suggest robust business operations, although financial leverage presents a risk factor. Analyst projections indicate a stable price outlook with no aggressive buy sentiments yet, suggesting caution in short-term commitments. As the industry evolves, potential growth can hinge on successful new product developments and market expansion.